Charles Sales
Neurology · Scottsdale, AZNPI 1740542463
Payments from drug & device makers
Across 87 payments — averaging $15.55 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$720
- Amgen$122
- UCB, Inc.$80
- Teva Pharmaceuticals USA, Inc.$73
- Genentech USA, Inc.$44
- Abbott$30
- plus $284 from 14 others
What the payments were for
- Food & beverage$1,28095%
- Education$735%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 55 | $720 |
| Amgen(2 entities) | 8 | $122 |
| UCB, Inc. | 3 | $80 |
| Teva Pharmaceuticals USA, Inc. | 1 | $73 |
| Genentech USA, Inc. | 2 | $44 |
| Abbott | 2 | $30 |
| Biogen | 2 | $28 |
| Eisai Inc. | 1 | $25 |
| SK Life Science, Inc. | 1 | $25 |
| Sunovion Pharmaceuticals Inc. | 2 | $24 |
| Lundbeck LLC | 1 | $24 |
| Bristol Myers Squibb | 1 | $22 |
| Mallinckrodt Hospital Products Inc. | 1 | $22 |
| Impel Pharmaceuticals Inc. | 1 | $21 |
| CSL Behring | 1 | $19 |
| Boston Scientific | 1 | $19 |
| GE HealthCare | 1 | $16 |
| Lilly USA, LLC | 1 | $15 |
| Biohaven Pharmaceuticals, Inc. | 1 | $12 |
| Sumitomo Pharma America, Inc. | 1 | $10 |
How this compares
$1,352 in reported general payments places this provider in the 40th percentile of 388 neurology providers in Arizona.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Gammagard LiquidImmun Glob G(Igg)/Gly/Iga Ov50 | 22 | $205,217 |
| Emgality PenGalcanezumab-Gnlm | 38 | $37,935 |
| AptiomEslicarbazepine Acetate | 11 | $16,180 |
| Aimovig AutoinjectorErenumab-Aooe | 21 | $15,114 |
| Nurtec OdtRimegepant Sulfate | 13 | $13,601 |
| Gabapentin | 121 | $2,266 |
| Memantine Hcl | 69 | $2,218 |
| Propranolol Hcl ErPropranolol Hcl | 21 | $1,628 |
| Primidone | 26 | $1,028 |
| Levetiracetam | 25 | $1,017 |
| Lacosamide | 14 | $936 |
| Duloxetine Hcl | 39 | $919 |
| Donepezil Hcl | 86 | $870 |
| Nortriptyline Hcl | 34 | $612 |
| Quetiapine Fumarate | 27 | $497 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Sunovion Pharmaceuticals Inc.Aptiom | $24 | $16,18011 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 388 neurology providers in Arizona.
Other neurology in Scottsdale
- Nida LaurinScottsdale$2.3M
- Allan BlockScottsdale$1.7M
- Virgilio Gerald EvidenteScottsdale$714K
- Brent GoodmanScottsdale$544K
- Dean WingerchukScottsdale$496K
- Meredith WicklundScottsdale$476K
- Erika Driver-DunckleyScottsdale$403K
- Amaal StarlingScottsdale$344K
- David SapersteinScottsdale$289K
- Maciej MrugalaScottsdale$243K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.